Search
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
go.drugbank.com/drugs/DB15728ExperimentalUmbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. … One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalNon-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.
Hydroquinidine
go.drugbank.com/drugs/DB15300InvestigationalHydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).
Categories: Antiarrhythmics, Class IaDotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawnDotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. … Dotatate gallium (Ga-68) explotes its ability to detect somatostatin receptor scintigraphy and this characteristic tends to change with tumor grade which gives Ga-68 dotate a high diagnostic value.
Synonyms: (68)Ga-DOTA-TATE, Ga 68 DOTATOCNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProlgolimab
go.drugbank.com/drugs/DB16740InvestigationalCategories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedDue to its relatively small molecular weight and small molecular diameter of 7 nm [A32168], technetium Tc-99m tilmanocept displays more rapid injection site clearance, high sentinel node extraction, and … It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label].
Ardeparin
go.drugbank.com/drugs/DB00407ApprovedWithdrawnArdeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.